Icebreaker.vc participates in Cytely's €3M seed funding round
Cytely, a deeptech startup focused on accelerating discovery to unlock human biology and cure all preventable diseases, has announced a new €3M seed funding round led by Ugly Duckling Ventures with participation from EstVCA member fund Icebreaker.vc.
The hardware-independent solution transforms ordinary microscopes into data-driven analysis tools that deliver statistically reliable results in minutes instead of months. At Lund University, the technology has already enabled faster progress in virology, and the company also reports use in cancer, diabetes, and muscle research.
"There's been a lot of talk that AI hasn't yet delivered real productivity gains yet. But after seeing what our portfolio company Cytely has achieved in biomedical research, it's hard not to rethink that," commented Lasse Lehtinen, General Partner at Icebreaker.vc on his LinkedIn post.
The new funding will accelerate Cytely's mission to accelerate discovery by making smart-microscopy accessible to every lab. It will support development, allowing any scientist to run sophisticated quantitative workflows via one-click assays and visual tools without specialized data skills. The funding expands intelligent acquisition capabilities that work with any microscope brand, automatically steering imaging to capture the most relevant biology in real time. It will also allow the development of a platform that enables researchers to share validated methods and reanalyze datasets, building on each other's work instead of starting from scratch. Looking ahead, the goal is to help build a global discovery engine that integrates knowledge across labs worldwide, moving toward predictive analysis and autonomous scientific discovery.
"Their vision is truly transformative. We're thrilled to lead this round and support the mission to make smart, data‑centric microscopy accessible to every lab," said Louise Lachmann, Partner at Ugly Duckling Ventures.
For more information, please visit Cytely's blog.
Newer
There are no newer news
